시장보고서

상품코드

1636336

세계의 파브리병 시장 보고서 : 유형별, 진단 및 치료별, 최종사용자별, 지역별(2025-2033년)

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2025-2033

발행일: 2025년 01월 | 리서치사:

IMARC | 페이지 정보: 영문 130 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

파브리병 시장 세계 시장 규모는 2024년 21억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 37억 달러에 달할 것으로 예상하며, 2025-2033년간 6.02%의 연평균 성장률(CAGR)을 보일 것으로 전망하고 있습니다. 파브리병 환자 수 증가와 유전자 치료 및 효소 보충 요법과 같은 효과적인 새로운 치료법에 대한 수요 증가가 시장을 주도하는 주요 요인 중 하나입니다.

파브리병(α-갈락토시다아제 A 결핍증)은 심각한 x-연쇄 리소좀 유전성 질환으로, 기름, 지방산, 왁스 등 다양한 지질 저장 성분과 지방 유사 성분의 대사에 필요한 효소 결핍으로 인해 발생합니다. 진단을 받지 않거나 치료하지 않고 방치하면 혈관 및 조직 막힘, 진행성 신부전, 신경 장애, 심지어 뇌졸중을 유발할 수 있습니다. 현재 파브리병은 효소대체요법(ERT)과 보조요법으로 치료할 수 있습니다. 이 외에도 신장 및 심장 문제의 발생을 억제하기 위해 유전자 검사, 혈액 검사 및 비경구 검사를 통해 추가로 진단 할 수 있습니다. 이러한 접근 방식을 통해 1차 및 2차 합병증 발생 위험을 예방하고 근본적인 효소 결핍을 개선할 수 있습니다. 그 결과, 병원과 전문 클리닉에서 파브리병의 적시 진단과 효과적인 치료를 위해 다양한 방법이 널리 사용되고 있습니다.

파브리병 시장 동향 :

파브리병 환자 수 증가와 환자 안정화를 위한 유전자 치료, 효소 대체 기질 감소 치료, 샤페론 치료 등 정밀하고 효과적인 치료법에 대한 수요 증가가 시장 성장의 주요 원동력이 되고 있습니다. 이에 따라 질병 치료를 위한 경구용 약물 및 캡슐에 대한 수요가 증가하고 있는 것도 성장을 가속하는 요인으로 작용하고 있습니다. 또한, 획기적인 질병 치료 옵션을 설계하기 위해 의료 부문에 투자하는 규제 기관의 유리한 이니셔티브는 시장 성장을 뒷받침하고 있습니다. 또한, 파브리병 진단 및 치료를 위한 원격 의료 솔루션과 재택 치료 환경의 도입 등 기술 발전이 시장 성장을 가속하고 있습니다. 또한, 파브리병에 대한 인식이 높아지면서 시장 성장을 견인하고 있습니다. 의사와 개인들 사이에서 조기 진단과 다양한 예방책이 가능하다는 인식이 높아지면서 시장 성장에 기여하고 있습니다. 모든 유형의 만성 질환에 취약한 노인 인구가 꾸준히 증가하고 있는 것도 시장 성장에 기여하는 요인입니다. 이 외에도 의료 인프라의 대폭적인 개선, 유전성 질환 치료의 발전을 위한 집중적인 노력 강화, 치료 및 약물 포트폴리오를 확대하기 위한 지속적인 연구개발 활동 등이 시장 전망을 밝게 하고 있습니다.

본 보고서에서 다룬 주요 질문

세계 파브리병 시장은 지금까지 어떻게 발전해왔고, 앞으로 어떻게 발전할 것인가?
파브리병 시장 세계 시장에서의 촉진요인, 억제요인 및 기회는 무엇인가?
주요 지역 시장은?
어느 국가가 가장 매력적인 파브리병 시장인가?
유형별 시장 분석은?
진단 및 치료 기반 시장 분석은?
최종 사용자별 시장 분석은?
세계 파브리병 시장 경쟁 구도는?
파브리병 시장 세계 시장 내 주요 기업은?

The global fabry disease market size reached USD 2.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.02% during 2025-2033. The increasing number of patients suffering from fabry disease and the escalating need for effective novel therapies, such as genetic and enzyme replacement therapy, represent some of the key factors driving the market.

Fabry disease, or alpha galactosidase-A deficiency, represents a severe x-linked lysosomal inherited disorder that is caused by the lack of enzymes that are required to metabolize various lipid storage and fat-like components, including oils, fatty acids, and waxes. If left undiagnosed or untreated, it might result in clogging of blood vessels and tissue, progressive kidney failures, nerve damage, and even strokes. Currently, fabry disease can be treated with the support of enzyme replacement therapies (ERT) and adjunct therapy. Apart from this, it can be further diagnosed through genetic, blood, and parenteral examinations to inhibit the occurrence of kidney and heart problems. These approaches prevent the risk of developing first and second-level complications and correct underlying enzyme deficiency. Consequently, hospitals and specialty clinics widely utilize various procedures for the timely diagnosis and effective treatment of the Fabry disease.

Fabry Disease Market Trends:

The increasing number of patients suffering from fabry disease and the escalating need for precise and effective therapies, such as genetic, enzyme replacement substrate reduction, and chaperone treatments to stabilize individuals from suffering disease, are primarily driving the market growth. In line with this, the rising demand for orally administered medications and capsule for disease treatment is acting as another growth-inducing factor. Additionally, the favorable initiatives being undertaken by regulatory bodies to invest in the healthcare sector for the designing of breakthrough disease treatment options are supporting the market growth. Moreover, significant technological advancements, such as the introduction of telemedicine solutions and home care settings for the diagnosis and treatment of Fabry disease, are favoring the market growth. The market is also significantly driven by the rising awareness regarding the disease. There is an increasing consciousness regarding the availability of early-stage diagnosis and multiple preventive measures amongst physicians and individuals, which is contributing to the market growth. The steadily increasing geriatric population, which is susceptible to any kind of chronic ailments, is another factor contributing to the market growth. Other factors, such as significant improvements in the healthcare infrastructure, an enhanced focus on the advancement of the genetic disease therapies, and continuous research and development (R&D) activities to expand treatment and medication portfolios, are creating a positive outlook for the market.

Key Market Segmentation:

Type Insights:

Type 1
Type 2
Others
The report has also provided a detailed breakup and analysis of the fabry disease market based on the type. This includes Type 1, Type 2 and others.

Diagnosis and Treatment Insights:

Diagnosis
Blood Test
Genetic Test
Parenteral Test
Others
Treatment
Enzyme Replacement Therapy
Oral Therapy
Adjunct Therapy
Others

End User Insights:

Hospitals
Homecare
Specialty Clinics
Others

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Fabry disease. Some of the factors driving the North America fabry disease market included the increasing prevalence of fabry disease and the ongoing approvals of advanced therapeutics by regional governments for the disorder treatment.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global fabry disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics, Freeline, Idorsia Pharmaceuticals Ltd, JCR Pharmaceuticals Co. Ltd, Protalix BioTherapeutics, Sangamo Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global fabry disease market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global fabry disease market?
What are the key regional markets?
Which countries represent the most attractive fabry disease markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the diagnosis and treatment?
What is the breakup of the market based on the end user?
What is the competitive structure of the global fabry disease market?
Who are the key players/companies in the global fabry disease market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Fabry Disease Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Type 1
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Type 2
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

7.1 Diagnosis
- 7.1.1 Market Trends
- 7.1.2 Key Segments
  - 7.1.2.1 Blood Test
  - 7.1.2.2 Genetic Test
  - 7.1.2.3 Parenteral Test
  - 7.1.2.4 Others
- 7.1.3 Market Forecast
7.2 Treatment
- 7.2.1 Market Trends
- 7.2.2 Key Segments
  - 7.2.2.1 Enzyme Replacement Therapy
  - 7.2.2.2 Oral Therapy
  - 7.2.2.3 Adjunct Therapy
  - 7.2.2.4 Others
- 7.2.3 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Homecare
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Specialty Clinics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Amicus Therapeutics
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Freeline
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 Idorsia Pharmaceuticals Ltd
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
- 14.3.4 JCR Pharmaceuticals Co. Ltd
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Protalix BioTherapeutics
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 Sangamo Therapeutics Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

세계의 파브리병 시장 보고서 : 유형별, 진단 및 치료별, 최종사용자별, 지역별(2025-2033년)

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2025-2033

파브리병 시장 동향 :

본 보고서에서 다룬 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 서론

제5장 세계의 파브리병 시장

제6장 시장 분석 : 유형별

제7장 시장 분석 : 진단 및 치료별

제8장 시장 분석 : 최종사용자별

제9장 시장 분석 : 지역별

제10장 성장 촉진요인 및 억제요인과 기회

제11장 밸류체인 분석

제12장 Porter의 Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도